Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.74 |
| ▸ | PPARG | P37231 | 2/20 | 0.63 |
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20477570 | 0.87 | EPHX2 (0.76) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL20477542 | 0.86 | EPHX2 (0.74) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL3577590 | 0.86 | EPHX2 (0.73) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL27920874 | 0.86 | MAPK14 (0.74) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL28649243 | 0.84 | EPHX2 (0.70) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL17339262 | 0.84 | EPHX2 (0.70) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL27931800 | 0.83 | EPHX2 (0.70) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL28145191 | 0.83 | EPHX2 (0.70) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL22987222 | 0.83 | EPHX2 (0.69) | EPHX2NR1H4PPARGPPARAHTR2C | |
| SCHEMBL21490290 | 0.82 | ROCK2 (0.75) | EPHX2NR1H4PPARGPPARAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | EPHX2 4180/4885NR1H4 1771/4885PPARG 3915/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | EPHX2 4490/4885NR1H4 1462/4885PPARG 1682/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | EPHX2 4490/4885NR1H4 1462/4885PPARG 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.